Adjuvant Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous SCC

By News Health
2 months Ago

(MedPage Today) — CHICAGO — Adjuvant cemiplimab (Libtayo) significantly improved disease-free survival (DFS) compared with placebo in patients at high risk of recurrence of cutaneous squamous-cell carcinoma (SCC), a phase III randomized trial…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115862

Author :

Publish date : 2025-06-02 18:52:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

EMA Greenlights Voranigo for IDH-Mutant Grade 2 Glioma

RFK Jr. and Jeffrey Epstein; Death Linked to Surgical Stapler; Rabies Cases Rising

Investigate Shortness of Breath: Here’s How

Study Pinpoints Candidiasis Risk With Dual IL-17A/F Blockade

'Hardline' BMA blocks emergency pleas for strike doctors to work

A vast bubble around a dying star is too big to comprehend